Skip to content
Screener

Alnylam Pharmaceuticals ALNY Q4 2025 Annual earnings

Reported February 12, 2026 · Before market open

Revenue$1.1BMiss by $52.1M
EPS$0.82Miss by $0.34
Revenue estimate$1.1B
EPS estimate$1.16

Next report

Oct 29, 2026 (in 2 months)
Revenue estimate$1.4B
EPS estimate$2.19

Financials

Q4 2025

Income statement

See full
Revenue$1.1B+84.9%
Gross profit$829.3M+69.1%
Operating income$131.7M+225%
Net income$111.5M+233%
EPS (diluted)$0.82+226%

Balance sheet

See full
Cash & equivalents$1.7B+71.2%
Total debt$270.6M-0.3%
Total equity$789.2M+1,076%
Total assets$5.0B+17.1%

Cash flow

See full
Operating cash flow$163.6M+273%
CapEx$23.3M+156%
Free cash flow$140.3M+235%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$52.54B+73.1%
Enterprise value$51.15B+72.5%
P/E188.9×—
P/S14.1×+0.6×

Profitability

See full
Gross margin81.8%-4.6pp
Operating margin13.5%+9.9pp
Net margin7.5%+4.6pp
FCF margin12.5%+11.1pp

Returns & leverage

See full
Return on equity65%—
Debt / equity0.3×-3.7×
Current ratio2.8×0.0×

FAQ

When did Alnylam Pharmaceuticals report Q4 2025 earnings?
Alnylam Pharmaceuticals (ALNY) reported Q4 2025 earnings on February 12, 2026 before market open.
What were Alnylam Pharmaceuticals's Q4 2025 revenue and EPS?
Alnylam Pharmaceuticals reported revenue of $1.1B and eps of $0.82 for Q4 2025.
Did Alnylam Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $1.1B by $52.1M. EPS missed the consensus estimate of $1.16 by $0.34.
How did Alnylam Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 84.9% from $593.2M a year earlier and eps grew 1266.7% from $0.06.
Where can I find Alnylam Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-007491) and the 10-K periodic report (0001628280-26-007497) directly on SEC EDGAR. The filing index links above go to sec.gov.